While there are no well-established pharmacogenetic interactions involving the STX11 gene and specific drugs currently, future therapeutic strategies might include drugs designed to modify STX11-related pathways to manage disorders like familial hemophagocytic lymphohistiocytosis type 4 (FHL4), where STX11 dysfunction leads to severe immune dysregulation. These future interactions could occur through either pharmacodynamic methods affecting immune cell behavior or pharmacokinetic routes that influence the effectiveness of immune-modulating therapies.